Press releases

Filter by year:

GeNeuro : financial information for the first quarter 2021

Geneva, Switzerland, April 9, 2021 – 6.00pm CEST 

Strong financial situation and visibility:

  • Net cash position of €4.8 million 
  • Debt free 
  • Company’s operations funded until Q2-2022

GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate update.

GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting

Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).

GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

Geneva, Switzerland, February 18, 2021 – 7:30 am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced the completed patient recruitment in its Phase 2 trial of temelimab in MS patients, conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden). Temelimab is a monoclonal antibody designed to neutralize a pathogenic retroviral envelope protein, pHERV-W Env

GeNeuro receives French state grant to accelerate research into the role of HERV proteins in COVID-19

Geneva, Switzerland, January 26, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced it has received an award from the French national research agency, ANR (Agence Nationale de Recherche), for its COVERI project focused on understanding the role of human endogenous retrovirus (HERV) proteins in the abnormal immune-inflammation or the neurological damages suffered by important subsets of COVID-19 patients.

GeNeuro: Cash position at December 31, 2020, Business Update and Outlook for 2021

Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.


Start Page      Previous Page      Results 11-16 of 16